Taşlı, Levent Pamukkale Üniversitesi - Tıp Fakültesi - Dermatoloji AD, Turkey , Kaçar, Nida Pamukkale Üniversitesi - Tıp Fakültesi - Dermatoloji AD, Turkey , Yıldız, Necibe Uşak Devlet Hastanesi - Dermatoloji Kliniği, Turkey , Şanlı, Berna Pamukkale Üniversitesi - Tıp Fakültesi - Dermatoloji AD, Turkey , Ergin, Şeniz Pamukkale Üniversitesi - Tıp Fakültesi - Dermatoloji AD, Turkey

The comparison of oral versus subcutaneous administration of methotrexate in plaque type psoriasis: A 5 - year retrospective analysis

22594

Aim: Psoriasis is a common, chronic, infl ammatory, multisystem disease affecting approximately 2% of the population. While oral methotrexate has been used in the treatment of psoriasis with success, subcutaneous (SC) form of methotrexate have also been developed. SC methotrexate has been recently found more effective than oral methotrexate in the same dosage in rheumatoid arthritis. In this study, we aimed to compare the efficacy and safety of SC versus oral administration of methotrexate in patients with psoriasis. Materials and Methods: We analyzed the records of the patients with plaque psoriasis under methotrexate therapy at our clinic from 2006 to 2010. Results: Thirty patients (20 SC and 10 oral) were enrolled. The ratio of Psoriasis Area Severity Index (PASI) 50 achievement at 4 weeks was 50% in SC group whereas only 10% in oral group (p=0.04). While the total methotrexate dosage taken until PASI 50 achievement within 16 weeks was greater in oral group (p=0.039), total methotrexate dosage did not differ between the groups in terms of PASI 75 achievement (p 0.05). Mean PASI changes from baseline were comparable at 12 and 16 weeks between the groups (p 0.05). Conclusion: That the mean PASI changes from baseline were comparable at 12 and 16 weeks between the groups shows SC and oral methotrexate have no superiority to each other. PASI 50 was achieved with SC methotrexate in more patients for 4 weeks. SC methotrexate can be used as an induction therapy.

131

Psoriasis , methotrexate , therapy , treatment , subcutaneous , oral

Pamukkale Medical Journal

135